Navigation Links
DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
Date:10/28/2009

y technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach®. DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.

Forward Looking Statements

Except for historical information, this news release contains certain forward-looking statements that represent our current expectations and beliefs concerning future events, and involve certain known and unknown risk and uncertainties. These forward-looking statements relate to belief concerning the speed of Levulan growth and its potential for additional growth and additional indications. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release. These factors include, without limitation, actions by health regulatory authorities, sufficiency of funds, the regulatory approval process, results of clinical trials, reliance on third party manufacturers, our patent portfolio, and other risks and uncertainties identified in DUSA's Form 10-K for the year ended December 31, 2008, and other SEC filings from time to time.

SOURCE DUSA Pharmaceuticals, Inc.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
2. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
3. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
4. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
5. BioMarin Acquires Huxley Pharmaceuticals, Inc.
6. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
7. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
9. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
10. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
11. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Decision Resources, one of the world,s ... and healthcare issues, finds that over 70 percent ... high need for diabetes drugs with novel mechanisms ... is a high need for additional DPP-IV inhibitors. ... excellent glucose lowering ability and physicians in particular ...
(Date:12/17/2009)... Dec. 17 Protalix BioTherapeutics, Inc. (NYSE-Amex: ... Sandra Lauterbach to Vice President, Sales and Commercial ... position, Ms. Lauterbach will be responsible for all ... taliglucerase alfa in accordance with the collaboration agreement ... as any other products that emerge from the ...
(Date:12/17/2009)... N.J., Dec. 17 BASF ... has approved the use of Aseptrol® S10 - ... industrial facilities, such as, schools, hospitals, government buildings, ... S10 - Tab is based on Chlorine dioxide ... delivers a broad spectrum disinfectant as stated ...
Breaking Medicine Technology:Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 2Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 4BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 2BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 3Nations Oldest Taxpayer Group Criticizes Committee Vote for Baucus Health Bill Hidden Tax Increases 59401 1Nations Oldest Taxpayer Group Criticizes Committee Vote for Baucus Health Bill Hidden Tax Increases 59401 2Global Bioenergies is Setting Up its Scientific Advisory Board and Obtains Proof of Concept for a Bioprocess Generating Gaseous Hydrocarbons From Rene 14455 1Global Bioenergies is Setting Up its Scientific Advisory Board and Obtains Proof of Concept for a Bioprocess Generating Gaseous Hydrocarbons From Rene 14455 2Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 14452 1Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 14452 2
(Date:12/17/2009)... Reportlinker.com announces that a new market research ... http://www.reportlinker.com/p0169956/Top-Ten-Worlds-Leading-Animal-Health-Companies.html ,, The report ... industry executives with strategically significant competitor information, ... and implementation of effective marketing and R&D ... To establish a comprehensive, factual ...
(Date:12/17/2009)... /PRNewswire-Asia/ -- China,s leading high-tech,healthcare group, Golden Meditech ... 801) is pleased to announce today that the ... known as,Pypo China Holdings Limited, made its debut ... a successful secondary offering. The shares of FunTalk ... , As of today, ...
(Date:12/17/2009)... recent Thomson Reuters study show that Chinese research output ... to nearly 112,000 in 2008. , Faculty of ... biomedical literature, has evaluated more than 530 papers from ... Chinese-authored papers were selected in 2004, this increased by ... even higher in 2009. , Jane Hunter, Managing Director ...
(Date:12/17/2009)... Inc. (Rutherfordton, N.C.), a management client since 1983, and ... were recently recognized as top-ranked Community Value Providers by ... ... Brentwood, Tenn. (PRWEB) December 17, 2009 -- ... N.C.), a management client since 1983, and Sturgis Hospital ...
(Date:12/17/2009)... Solutions, and Scientific Studies Important ,for the R&D Informatics Industry, ... ... 17, 2009 -- Cambridge Healthtech Institute is pleased to announce ... 2nd Annual Adopting R&D Informatics Systems conference to be held ... in San Francisco, CA. This meeting has been integrated in ...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 4Health News:Golden Meditech's Associate Company Debuted on NASDAQ 2Health News:China rapidly catching up in research impact 2Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3
... Alliance,today welcomed the election of Senator Barack Obama as ... working with President-elect Obama as he confronts,that challenge of ... another 7,500 every day," said Carol Bergman, Acting Director ... Rubin and others have recently stated, the,economic crisis must ...
... ALEXANDRIA, Va., Nov. 5 Health Service,Online has ... at,Pharmacies: Are Drug Prices Higher in Poor Areas," ... RPh, National Community Pharmacists Association,(NCPA) executive vice president ... study by Dr. Walid Gellad is helpful in ...
... Foundation (NSSF) - the trade association for the firearms,ammunition, ... in response to study results from the Centers for ... Health, showing no,evidence that lead or "traditional" ammunition pose ... The CDC report on human lead levels of ...
... don,t affect timing of birth, study finds , , WEDNESDAY, Nov. ... increase a woman,s risk for preterm delivery, but most kinds ... The study, released by the research institute RTI International, looked ... four may be associated with preterm birth: being in debt; ...
... Mass. November 05, 2008 A new study published ... used on multiple sclerosis (MS) patients to determine if the ... those at-risk for progression of disability. , MS affects approximately ... 2.5 million worldwide. It is the most common cause of ...
... Tips To Choose One That Works, ROCHESTER, Minn., Nov. ... facts to help size up the best skin,moisturizers., Retail ... for everything from eyelids to feet at prices from less ... it,s hard to choose all wrong.,Most -- if not all ...
Other Medicine News:Health News:Global AIDS Alliance Welcomes Election of Barack Obama 2Health News:NCPA Statement on Florida Study About Prescription Drug Prices in Underserved Areas 2Health News:Firearms Industry Statement on Results of CDC Blood Lead Levels in Hunters Study 2Health News:Debt-Linked Stress May Spur Premature Delivery 2Health News:Multiple sclerosis progression can be predicted with MRI 2Health News:November 2008 Mayo Clinic Health Letter Highlights Moisturizers, Potatoes and Varicose Veins 2Health News:November 2008 Mayo Clinic Health Letter Highlights Moisturizers, Potatoes and Varicose Veins 3Health News:November 2008 Mayo Clinic Health Letter Highlights Moisturizers, Potatoes and Varicose Veins 4
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....
... of flexible lighting products. The first is ... different sizes 5", 10", and 15" (refers ... light). These lights are for use in ... ,The second group of flexible lights is ...
... groups of flexible lighting products. The first ... three different sizes 5", 10", and 15" ... the light). These lights are for use ... ,The second group of flexible lights ...
Medicine Products: